Login

Axonics, Inc. 8-K SEC Filings

Filed On Filing
15 Nov 2024 8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +4 more

Section 1. ANNUAL MEETING. The annual meeting of the stockholders of Axonics, Inc. (the “Corporation”), for the purpose of electing directors and for the transaction of such other business as may be brought before the meeting, shall be h...

07 Nov 2024 8-K: Results of Operations and Financial Condition

IRVINE, Calif. – November 7, 2024 – Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today report...

01 Aug 2024 8-K: Results of Operations and Financial Condition

Generated record revenue, gross margin and net income in 2Q24

30 Apr 2024 8-K: Results of Operations and Financial Condition

IRVINE, Calif. – April 30, 2024 – Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial res...

04 Apr 2024 8-K: Other Events

As previously disclosed, on January 8, 2024, Axonics, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Boston Scientific Corporation, a Delaware corporation (“Boston...

25 Mar 2024 8-K: Submission of Matters to a Vote of Security Holders; Other Events

IRVINE, Calif – (BUSINESS WIRE) – Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics’ merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results fr...

28 Feb 2024 8-K: Results of Operations and Financial Condition

IRVINE, Calif – (BUSINESS WIRE) – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial result...

08 Jan 2024 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation

Exhibit A – Second Amended and Restated Certificate of Incorporation of the Surviving Corporation

08 Jan 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

IRVINE, Calif – (BUSINESS WIRE) – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unau...

30 Oct 2023 8-K: Results of Operations and Financial Condition

Generated quarterly revenue of $93.1 million, an increase of 32% year over year

04 Oct 2023 8-K: Departure/Election of Directors or Officers; Compensation

This Executive Employment Agreement (this “Agreement”) is dated as of October 2, 2023 by and between Axonics, Inc., a Delaware corporation (the “Company”), and Raymond W. Cohen (“Executive”).

21 Aug 2023 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

IRVINE, Calif. – August 21, 2023 – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. De...

27 Jul 2023 8-K: Results of Operations and Financial Condition

Generated quarterly revenue of $92.9 million, an increase of 35% year over year

27 Jun 2023 8-K: Submission of Matters to a Vote of Security Holders

Axonics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 26, 2023. On April 27, 2023, the record date (the “Record Date”) for determining stockholders entitled to vote at the Annual Meeting, th...

18 May 2023 8-K: Other Events

We have acted as counsel to Axonics, Inc., a Delaware corporation (the “Company”), in connection with the Registration Statement on Form S-3 (No. 333-271663) (the “Registration Statement”) filed by the Company with the Securities and Exc...

01 May 2023 8-K: Results of Operations and Financial Condition

Generated quarterly revenue of $70.7 million, an increase of 46% year over year

06 Apr 2023 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

THIS LEASE is made as of April 1, 2023, by and between SAND CANYON BUSINESS CENTER I LLC, a Delaware limited liability company, hereafter called “Landlord,” and AXONICS, INC., a Delaware corporation, hereafter called “Tenant.”

01 Mar 2023 8-K: Results of Operations and Financial Condition

Generated record quarterly revenue of $86 million, an increase of 62% y/y

11 Jan 2023 8-K: Results of Operations and Financial Condition

4Q22 total company net revenue expected to be $85.6 to $86.0 million, an increase of 61% y/y

31 Oct 2022 8-K: Results of Operations and Financial Condition

IRVINE, Calif. – October 31, 2022 – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial resu...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support